Fortress - נכסים נקיים למניה בודדת FBIO

The historical book value per share for Fortress Biotech, Inc. (FBIO), where the value is maintained at 4.93, confirms the strategy of monetizing FDA-approved drugs to support new research. The incubator's diversified approach minimizes risks associated with individual product failures. Meanwhile, management is effectively scaling the holding's value by creating and taking promising biotech subsidiaries public.

Book value per share is calculated as the difference between a company's total assets and liabilities divided by the number of outstanding shares, which determines the actual value of capital for the shareholder. For the Fortress Biotech, Inc. (FBIO) holding structure under the leadership of Lindsay Rosenwald, this metric reflects the efficiency of managing subsidiary assets and securing external financing, as clearly captured by the current book value per share.